Lupin Enters Licensing Agreement with Gan & Lee for GLP-1 Agonist

Lupin Limited has announced an exclusive License, Supply, and Distribution agreement with Gan & Lee Pharmaceuticals for the novel GLP-1 receptor agonist, Bofanglutide. This agreement provides Lupin with exclusive rights to commercialize and distribute Bofanglutide in India. The announcement was made on December 29, 2025, and aligns with Lupin’s strategic focus on expanding its diabetes and obesity treatment portfolio.

The financial terms of the agreement between Lupin and Gan & Lee Pharmaceuticals have not been disclosed in the filing. The agreement is structured to allow Lupin exclusive commercialization rights within the Indian market, focusing on the distribution of Bofanglutide, a fortnightly GLP-1 receptor agonist.

Bofanglutide is designed for the treatment of adults with type 2 diabetes and for weight management in overweight or obese individuals. It is a fortnightly injection, offering a dosing schedule of once every two weeks, which is less frequent than the weekly injections of existing GLP-1 alternatives. Clinical data indicate that Bofanglutide provides weight loss results comparable to or better than current alternatives, while maintaining safety and tolerability consistent with the GLP-1 class. This product aims to reduce both blood glucose levels and body weight effectively.

The agreement comes at a time when obesity and diabetes are significant health concerns in India. Approximately 174 million adults are classified as overweight, with around 50 million considered obese. Diabetes affects approximately 90 million adults in the country. The partnership with Gan & Lee Pharmaceuticals is part of Lupin’s strategy to address these growing health challenges by expanding its portfolio in the metabolic health sector.

The timeline for the commercialization and distribution of Bofanglutide in India has not been specified in the filing. However, Lupin’s exclusive rights under the agreement suggest a focus on rapid market entry to address the urgent health needs related to diabetes and obesity.

Gan & Lee Pharmaceuticals is a Chinese company known for developing the first domestic insulin analog in China. The company has a portfolio of six core insulin products and is expanding its presence in international markets. Gan & Lee aims to provide superior treatment options for metabolic diseases and has received GMP inspection approval from the European Medicines Agency in 2024.

Lupin Limited is a global pharmaceutical leader headquartered in Mumbai, India. The company specializes in branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Lupin operates in over 100 markets and focuses on multiple therapy areas, including respiratory, cardiovascular, anti-diabetic, and women’s health. The company is committed to improving patient health outcomes through its subsidiaries and strategic partnerships.